Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha TeknovaTKNO -4.22%61 EV-to-EBITDA is -40.32 as of Sep. 05, 2026. GuruFocus rates TKNO with a GF Score™ of 61/100 and a GF Value™ of $4.45 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 726 Drug Manufacturers companies, Alpha Teknova ranks worse than 137740.91% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alpha Teknova's enterprise value is $381.50 Mil.
Alpha Teknova's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-9.46 Mil. Therefore, Alpha Teknova's EV-to-EBITDA for today is -40.32.
The historical rank and industry rank for Alpha Teknova's EV-to-EBITDA or its related term are showing as below:
TKNO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -175.4 Med: -11.31 Max: 128.32
Current: -40.32
During the past 7 years, the highest EV-to-EBITDA of Alpha Teknova was 128.32. The lowest was -175.40. And the median was -11.31.
TKNO's EV-to-EBITDA is ranked worse than 100% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.55
vs TKNO: -40.32
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alpha Teknova's PE Ratio (TTM) for today is calculated as:
Alpha Teknova's share price for today is $6.92.
Alpha Teknova's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Alpha Teknova's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alpha Teknova's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Teknova EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alpha Teknova's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alpha Teknova's EV-to-EBITDA falls into.
Alpha Teknova's current Enterprise Value is $381.50 Mil.
Alpha Teknova's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Teknova (TKNO) has a EV-to-EBITDA of -40.32 as of Sep. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alpha Teknova. According to the industry distribution chart, Alpha Teknova ranks #999999 out of 726 companies in the Drug Manufacturers industry.
Is Alpha Teknova's EV-to-EBITDA too high?
Alpha Teknova's current EV-to-EBITDA is -40.32. Based on the distribution chart, Alpha Teknova ranks #999999 out of 726 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alpha Teknova has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alpha Teknova's EV-to-EBITDA compare to NIKA and BIOA?
According to the Drug Manufacturers industry distribution chart, Alpha Teknova ranks #999999 out of 726 companies for EV-to-EBITDA. This places Alpha Teknova in the lower half of its industry. The industry median EV-to-EBITDA is 13.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.55, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alpha Teknova. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Teknova's current EV-to-EBITDA is -40.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Teknova stock overvalued right now?
Based on GuruFocus' analysis, Alpha Teknova (TKNO) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.45, compared to a current price of $6.92 — trading 55.5% above its estimated fair value. The current EV-to-EBITDA is -40.32. Alpha Teknova's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alpha Teknova (TKNO), the current EV-to-EBITDA is -40.32 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alpha Teknova (TKNO) Overvalued in 2026?
Based on GuruFocus' analysis, Alpha Teknova stock appears to be overvalued.
The current stock price of $6.92 is trading 55.5% above its estimated GF Value™ of $4.45.
GuruFocus considers Alpha Teknova to be Significantly Overvalued.
Key valuation signals for TKNO:
EV-to-EBITDA: -40.32
GF Value™: $4.45 vs. price of $6.92 (55.5% above fair value)
No single metric tells the full story. See the TKNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
61GF Score
Get the complete analysis for TKNO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TKNO has been successfully added to your 
